ProMetic Life Sciences Inc.
TSX : PLI

ProMetic Life Sciences Inc.

December 17, 2007 11:10 ET

ProMetic Life Sciences Congratulates Dr. Robert G. Rohwer on Being Named a Top 50 Scientist by Scientific American

MONTREAL, QUEBEC, CANADA--(Marketwire - Dec. 17, 2007) - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") extends its congratulations to Robert G. Rohwer, Ph.D., Director, Molecular Neurovirology Laboratory, Veteran's Affairs Medical Center and Associate Professor of Neurology, University of Maryland School of Medicine, for being named among Scientific American magazine's SA 50, the magazine's sixth annual listing of the top 50 scientists of 2007. Dr. Rohwer was named for his work on filtering prions from blood, which eventually evolved into the P-Capt™ filter, a product designed to remove infectious prions potentially present in red blood cell concentrates in order to reduce the risk of transmission of varient-Creutzfelt-Jakob disease ("vCJD" otherwise known as mad cow disease in humans). The P-Capt™ filter, which has received European Regulatory Approval (CE mark), is co-promoted in the United Kingdom by Pathogen Removal and Diagnostic Technologies ("PRDT"), a joint venture between ProMetic Life Sciences Inc. ("ProMetic") and The American Red Cross, and PRDT's commercial and manufacturing partner MacoPharma, SA.

"We are very proud to be involved with Dr. Rohwer and his research, and are honored to be associated with the science behind his receipt of this prestigious award," said Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic. "We look forward to a long, productive collaboration with Dr. Rohwer and extend to him and to his research team our heartfelt congratulations."

For 30 years Dr. Rohwer has conducted research on transmissible spongiform encephalopathies ("TSEs"), a class of fatal neurodegenerative diseases, including Creutzfeldt-Jakob disease, which infects humans, scrapie, which infects sheep and goats, and Bovine Spongiform Encephalopathy ("BSE"), a newly emergent disease that affects both cattle and humans. Dr. Rohwer's studies on the kinetics of inactivation of the TSE agents have provided the scientific foundation for disinfection guidelines in the U.S. and worldwide.

Recently Dr. Rohwer and his laboratory team have conducted critical experiments establishing the level, distribution and transmissibility of TSE infectivity in blood, the results of which are being used to shape government policies on TSE risk management around the world. Dr. Rohwer consults on the management of TSE risks for the World Health Organization, the European Commission, Health Canada, the U.S. Food and Drug Administration, the American Red Cross, the U.S. Department of Agriculture and numerous commercial clients in the biotechnology, pharmaceutical, agribusiness and related industries, including ProMetic Life Sciences Inc.

About PRDT

PRDT is a joint venture established in April 2002 by The American Red Cross and ProMetic Life Sciences Inc., and allows for the exchange of technology and knowledge between the two organizations. PRDT's main goal is to develop products and devices to remove and detect different pathogens from biological sources. This research augments work that ProMetic, the American Red Cross and PRDT's scientific founders have been conducting independently for many years.

About MacoPharma

MacoPharma (www.macopharma.com) is an innovator in global healthcare with expertise in the fields of transfusion and infusion. The Company has become the largest supplier of in-line leucodepletion filtration sets in Europe and is expanding its efforts into the biotherapy field by developing products for cell expansion, in addition to cell/organ processing and freezing. Headquartered in the Lille metropolitan area (France), MacoPharma has three manufacturing facilities in Europe and its products are now sold into more than 55 countries worldwide. One of MacoPharma's aims is to provide a comprehensive range for the reduction of infectious agents in plasma, platelets and red cells. This is conducive with the MacoPharma product development strategy of the continuous quest, through partnerships, for improved safety, efficacy, and quality of transfusion, infusion and biotherapy.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2006, under the heading "Risk Factors." As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason.

Contact Information